Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Handa PharmaceuticalsROCO:6620 -1.28%75 EBITDA Margin % is 86.29% as of Dec. 2025, which is 2702% above its 10-year median of 3.08. GuruFocus rates ROCO:6620 with a GF Score™ of 75/100 and a GF Value™ of NT$183.95 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 959 Drug Manufacturers companies, Handa Pharmaceuticals ranks better than 98.02% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Handa Pharmaceuticals EBITDA Margin % Related Terms
Handa Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Handa Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6620 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Handa Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Handa Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Handa Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Handa Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Handa Pharmaceuticals (ROCO:6620) has a EBITDA Margin % of 86.29% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Handa Pharmaceuticals and its competitors. This is 2702% above median its historical median of 3.08. According to the industry distribution chart, Handa Pharmaceuticals ranks #19 out of 959 companies in the Drug Manufacturers industry, placing it in the top 2%.
Is Handa Pharmaceuticals' EBITDA Margin % too high?
Handa Pharmaceuticals' current EBITDA Margin % of 86.29% is 2702% above median its 10-year median of 3.08. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Handa Pharmaceuticals' value of 86.29% is 588.1% above this industry median. Based on the distribution chart, Handa Pharmaceuticals ranks #19 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Handa Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Handa Pharmaceuticals' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Handa Pharmaceuticals ranks #19 out of 959 companies for EBITDA Margin %. This places Handa Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.54. Handa Pharmaceuticals' value of 86.29% is 588.1% above this benchmark. While the company's 10-year median is 3.08 vs. the industry median of 12.54, Handa Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Handa Pharmaceuticals's current EBITDA Margin % of 86.29% is 588.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Handa Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Handa Pharmaceuticals's current EBITDA Margin % is 86.29%, which is 2702% above median its own 10-year median of 3.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Handa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Handa Pharmaceuticals (ROCO:6620) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$183.95, compared to a current price of NT$84.70 — trading 54% below its estimated fair value. The current EBITDA Margin % is 86.29%, which is 2702% above median its 10-year median of 3.08 and 588.1% above the Drug Manufacturers industry median of 12.54. Handa Pharmaceuticals' overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Handa Pharmaceuticals (ROCO:6620), the current EBITDA Margin % is 86.29% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Handa Pharmaceuticals (ROCO:6620) Overvalued in 2026?
Based on GuruFocus' analysis, Handa Pharmaceuticals stock appears to be undervalued.
The current stock price of NT$84.70 is trading 54% below its estimated GF Value™ of NT$183.95.
GuruFocus considers Handa Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ROCO:6620:
EBITDA Margin %: 86.29% (2702% above median its 10-year median of 3.08)
GF Value™: NT$183.95 vs. price of NT$84.70 (54% below fair value)
Industry Position: 588.1% above the Drug Manufacturers median (#19 of 959)
No single metric tells the full story. See the ROCO:6620 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Handa Pharmaceuticals Inc is a Taiwan-based specialty pharmaceutical company. It is engaged in the development of niche drugs. The company focuses on the development of high-barrier/patentable niche products.
75GF Score
Get the complete analysis for ROCO:6620
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6620 has been successfully added to your 
